Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Desmopressin Nasal Spray Solution USP, 10 mcg/0.1 mL per Spray, 5 mL bottle. It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad. The group now has more than 160 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
Desmopressin Nasal Spray is indicated as an antidiuretic replacement therapy in the management of central diabetes insipidus, polyuria (excessive urination) and polydipsia (drinking excessive amounts of fluids) following head trauma or surgery in the pituitary region and nocturia (excessive urination at night).
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: